Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: Correlation with histopathology

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 2, 2011, Pages 122-128

  Jensen, Thor Knak ^a   Holt, Per ^a   Gerke, Oke ^b,c   Riehmann, Morten ^a   Svolgaard, Birgitte ^a   Marcussen, Niels ^a   Bouchelouche, Kirsten ^b,d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b PET and Cyclotron Unit   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

FDG PET CT; invasive bladder cancer; lymph node staging; MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79951845515     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2010.544672     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-49.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49.
3. MacVicar AD. Bladder cancer staging. BJU Int 2000; 86(Suppl 1):111-22.
4. Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol 2008;20:307-14. (Pubitemid 351507552)
5. Beyersdorff D, Zhang J, Schoder H, Bochner B, Hricak H. Bladder cancer: can imaging change patient management? Curr Opin Urol 2008;18:98-104. (Pubitemid 350307538)
6. Setty BN, Holalkere NS, Sahani DV, Uppot RN, Harisinghani M, Blake MA. State-of-the-art cross-sectional imaging in bladder cancer. Curr Probl Diagn Radiol 2007;36: 83-96. (Pubitemid 46291635)
7. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008;179: 34-45. (Pubitemid 350225698)
8. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-21. (Pubitemid 46634756)
9. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006;36: 51-72. (Pubitemid 41779367)
10. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-20. (Pubitemid 27299740)
11. Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764-70. (Pubitemid 47604977)
12. Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 2007;178:1218-23.
13. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75. (Pubitemid 32120143)
14. Newcombe RG, Altman DG. Proportions and their differences. In: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. London: BMJ Books; 2000.
15. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004;233:449-56. (Pubitemid 39423804)
16. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:1412-17. (Pubitemid 41746845)
17. Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2009;57: 641-7.
18. Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009;27:4314-20.
19. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357-68. (Pubitemid 41185156)
20. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using 11C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 2002;29:1283-8. (Pubitemid 44392207)
21. Picchio M, Treiber U, Beer AJ, Metz S, Bossner P, van Randenborgh H, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006;47: 938-44. (Pubitemid 46939945)
22. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996;37:180-5. (Pubitemid 126710100)
23. Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S, Nino-Murcia M, et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int 2006;77:69-75. (Pubitemid 44034422)